Landscapes / Companies
Furthest along
5 approved
4 in Phase 3
Drugs
15
in active trials · 68 in all
Trials
35 active
254 since 2021
Drugs15
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | 13 Mar 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 13 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Immunoglobulin A Nephropathy, IgA Nephropathy and 4 more | ||||
| Open drug page | |||||
Norepinephrine, dopamine and serotonin reuptake inhibitor |
Approved | 27 May 2027Phase 3 trial completes | |||
| Next date | 27 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Attention Deficit Hyperactivity Disorder (ADHD), Attention-Deficit Hyperactivity Disorder(ADHD) and 2 more | ||||
| Open drug page | |||||
OPC-34712FUMnot checked |
— |
Approved | Sep 2027Phase 3 trial completes | ||
| Next date | Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Acute Schizophrenia | ||||
| Open drug page | |||||
Vasopressin V2 receptor antagonist |
Approved | 28 Dec 2028Phase 3 trial completes | |||
| Next date | 28 Dec 2028 · Phase 3 trial completes | ||||
| Also tested for | Autosomal Recessive Polycystic Kidney (ARPKD) | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Lower-risk Myelodysplastic | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis (AD) | ||||
| Open drug page | |||||
— |
Phase 3 | 1 Nov 2027Phase 3 trial completes | |||
| Next date | 1 Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Phenylketonuria, Phenylketonuria (PKU) | ||||
| Open drug page | |||||
— |
Phase 3 | Mar 2028Phase 3 trial completes | |||
| Next date | Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Generalized Anxiety Disorder, Schizophrenia | ||||
| Open drug page | |||||
— |
Phase 3 | 29 Sep 2028Phase 3 trial completes | |||
| Next date | 29 Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Jun 2027Phase 1/2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Diabetes Mellitus, Type 1, Hypoglycemia and 15 more | ||||
| Open drug page | |||||
VIS954not checked |
— |
Phase 2 | 13 Mar 2029Phase 2 trial completes | ||
| Next date | 13 Mar 2029 · Phase 2 trial completes | ||||
| Also tested for | Antineutrophil Cytoplasmic Antibody-associated Vasculitis, Inflammatory Skin Diseases | ||||
| Open drug page | |||||
SEP-380135not checked |
— |
Phase 1 | 2 Dec 2026soonPhase 1 trial completes | ||
| Next date | 2 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Schizophrenia | ||||
| Open drug page | |||||
— |
Phase 1 | 25 Aug 2027Phase 1 trial completes | |||
| Next date | 25 Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Diabetes Insipidus | ||||
| Open drug page | |||||
— |
Phase 1 | 20 Nov 2028Phase 1 trial completes | |||
| Next date | 20 Nov 2028 · Phase 1 trial completes | ||||
| Also tested for | Rheumatoid Arthritis, Systemic Lupus Erythematosus and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA) and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 53 other drugs
- SEC filings
- None: it does not file with the US SEC
- Registry names
- 7 names in ClinicalTrials.gov Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Co., Ltd.
Otsuka Beijing Research Institute
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Factory, Inc.
Otsuka Australia Pharmaceutical Pty Ltd
Korea Otsuka International Asia Arab - Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021